Defilade Capital Management, L.P.
Position in DNLI — Denali Therapeutics Inc.
CIK 2088557
EMERYVILLE, CA
Position in DNLI
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$26,111,404
+$15,269,073 QoQ
Shares Held
1,359,969
+107.1% QoQ
Ownership
0.857%
of shares outstanding
% of Portfolio
3.67%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Defilade Capital Management, L.P. holds $230,552,258 across 14 Biotechnology names. DNLI ranks #3 (11.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
194,909 | $31,871,519 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
315,972 | $30,728,277 | |
| 3 | DNLI |
Denali Therapeutics Inc.
This page
|
1,359,969 | $26,111,404 | |
| 4 | PTCT |
Ptc Therapeutics, Inc.
|
376,165 | $25,628,121 | |
| 5 | OLMA |
Olema Pharmaceuticals, Inc.
|
1,504,536 | $22,432,631 | |
| 6 | EVMN |
Evommune, Inc.
|
678,589 | $15,600,761 | |
| 7 | COGT |
Cogent Biosciences, Inc.
|
352,590 | $13,571,189 | |
| 8 | NUVL |
Nuvalent, Inc.
|
129,950 | $13,313,377 |
All Filings in DNLI
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $26,111,404 | 1,359,969 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $10,842,331 | 656,713 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||